ImmunityBio Q4 Loss Narrows to $0.06, Revenue Climbs to $38.3M
ImmunityBio posted a Q4 adjusted loss of $0.06 per share, beating consensus by $0.02 and improving from a $0.15 loss a year ago. Revenue rose to $38.29 million, topping estimates by 3.2% and up from $7.55 million year-over-year, fueling a 16% intraday share jump and a 339% gain since January.
1. Q4 Earnings Beat
ImmunityBio reported an adjusted loss of $0.06 per share for Q4, compared with a year-ago loss of $0.15. The $0.02 per share outperformance translated into a 25% positive surprise against consensus estimates.
2. Record Year-Over-Year Revenue Growth
Revenue surged to $38.29 million, up from $7.55 million a year earlier, marking a 407% year-over-year increase. The result exceeded forecasts by 3.19%, extending the company’s streak of revenue beats.
3. Stock Reaction and Momentum
Shares jumped 16% on the day of the release and have climbed approximately 339% since the start of the year, far outpacing the S&P 500’s 0.9% gain. The spike reflects investor enthusiasm over both the earnings surprise and rapid revenue expansion.
4. Outlook and Dependencies
Investors will look for management’s commentary on future milestones during the upcoming earnings call. Current consensus forecasts call for a Q1 loss of $0.08 per share on $41.75 million in revenue and a fiscal-year loss of $0.32 per share on $205.6 million in revenue.